0.1600GBP0.00%Mkt Cap: 2.71M $P/E: —1d ago
ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperi…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap2.71M $
Enterprise Value-77.44K $
Revenue (TTM)40.24K $
Gross Profit-8.02K $
Net Income (TTM)-2.86M $
Revenue/Share0.0000 USD
Last Price0.1600 GBP
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees11
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.04
EV/Revenue-1.92
P/S71.55
P/B0.42
EPS (TTM)-0.01
EPS (Forward)-1.86
52W Range
0.13004% of range0.8490
52W High0.8490 GBP
52W Low0.1300 GBP
Profitability
Gross Margin-19.92%
Oper. Margin-2832.24%
EBITDA Margin0.00%
Profit Margin-7115.13%
ROE-78.18%
ROA-84.82%
Growth
Revenue Growth-37.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.94M $
CapEx (TTM)17.42K $
FCF Margin-3104.29%
FCF Yield-46.10%
Net Debt-1.01M $
Net Debt/EBITDA0.50
Balance Sheet
Debt/Equity0.00
Current Ratio4.62
Quick Ratio4.15
Book Value/Sh0.0040 GBP
Cash/Share0.0010 GBP
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBP
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:125
Split DateApr 6, 2020
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.32B
Float699.28M
Insiders8.95%
Institutions0.00%
Technical
SMA 500.1631 (-1.9%)
SMA 2000.2691 (-40.5%)
Beta-0.62
S&P 52W Chg18.16%
Avg Vol (30d)15.72M
Avg Vol (10d)5.36M
Technical Indicators
RSI (14)48.5
MACD-0.0012
MACD Signal-0.0023
MACD Hist.+0.0011
BB Upper0.1691 GBP
BB Middle0.1583 GBP
BB Lower0.1474 GBP
BB Width13.77%
ATR (14)0.0176 GBP
Vol Ratio (20d)0.01x